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Abstract: Mannitol infusion is commonly used in the treatment of intracranial hypertension following
traumatic brain injury. It has long been known to have stability issues, specifically, mannitol
recrystallises from solutions greater than 10% w/v in ambient conditions. This can happen at any time,
whether on the pharmacy shelf or during a medical procedure. This study describes the stability
limits of 20% w/v mannitol infusion (the most common strength used clinically) and proposes a
number of safer, stable and tuneable hyperosmotic formulations of mannitol in combination with
clinically acceptable osmotic agents (NaCl, sorbitol and glycerol).
Keywords: mannitol instability; raised intracranial pressure; intracranial hypertension; traumatic
brain injury; reformulation; mannitol; recrystallisation
1. Introduction
Traumatic brain injury (TBI) is one of the greatest causes of death and disability in those aged
under 40 [1], and with 69 million cases of TBI each year [2], this presents a critical health problem.
The pathological mechanism behind this death and disability (besides the immediate trauma) is
cerebral oedema, which elevates intracranial pressure, and can result in cerebral ischaemia [3]; as such,
intracranial hypertension is a medical emergency.
As increases in intracranial pressure (ICP) are inversely proportional to survival [4], treatment aims
to reduce ICP <20 mmHg as soon as possible [5]. Commonly, intravenous mannitol or hypertonic saline
infusions are employed. There are two mechanisms which contribute to their effect: (1) creation of an
osmotic gradient, which draws cerebral fluid across the blood–brain barrier and into the plasma and,
(2) plasma expansion with associated reductions in blood haematocrit and viscosity [6]. Although there
is significant debate regarding the choice of hyperosmolar therapy [7–10]—highlighted by the recent
Sugar or Salt trial [11]—ultimately, the choice of hyperosmolar agent is a complex decision [5], and
each treatment option carries its own advantages and disadvantages.
From a formulation perspective, the stability of mannitol infusion is unreliable as precipitation
commonly occurs during storage of mannitol in concentrations >10% w/v, such as those employed in
TBI. The current solution is to heat the mannitol infusions up to 60 ◦C (often in a sink or a bucket of hot
water), wait for the crystals to dissolve and cool the solution back down to body temperature prior to
administration. As intracranial hypertension is a medical emergency, this method is not rapid enough
and carries a significant risk of patient harm. Further, in the ambient temperatures expected in clinical
environments (15–25 ◦C), mannitol can precipitate during a procedure. Although risks can be reduced
by using a filter at the end of the IV set, Lionel and Hrishi have noted the possibility of microparticulate
embolism [12], not to mention the now unknown mannitol concentration. The instability of mannitol
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solutions is further highlighted by the red warning on the label reminding clinicians to, “carefully
inspect the contents of the solution for crystals immediately before use.” (Figure 1). This places further
emphasis on the need for new formulations of this important agent.
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confirms its purity. These results are unsurprising as the 𝛼 polymorph has been shown to nucleate 
from supersaturated solutions and then transform to the stable 𝛽 polymorph following Oswald’s rule 
of stages [18]. Although the existence of a mannitol hydrate has been documented in the literature, it 
is unstable [19]. This behaviour has been studied extensively for mannitol in aqueous systems 
[13,15,16,18]. 
 
Figure 2. Powder X-Ray Diffraction (PXRD) (left) and Differential Scanning Calorimetry (DSC) (right) 
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Figure 1. Photograph of mannitol infusion solution (left) and crystals were taken from solution after
precipitation (right).
Mannitol solubility has been extensively studied for various pharmaceutical applications such
that there is a comprehensive understanding of the thermodynamic characteristics of mannitol and
the interplay between its various polymorphs in the liquid and solid states [13–16]. The purpose of
this study is not to replicate this but to understand how to optimise this formulation, particularly as
the properties of mannitol in a 20% w/v infusion solution within the clinical environment are not
well understood.
Therefore, we set out to understand the stability limits of mannitol 20% w/v to create a safer,
stable hyperosmotic formulation via combination with clinically acceptable osmotic agents (NaCl,
sorbitol and glycerol [7,17]).
2. Materials and Methods
2.1. Materials
All materials and reagents were purchased from Sigma-Aldrich at the highest purity available
and used as received. Mannitol 20% w/v solution for infusion was donated as a gift from the University
Hospital Limerick, purchased originally from Fresenius Kabi (batch number: 18M201, expiry: 02/2023).
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2.2. Methods
2.2.1. Powder X-ray Diffraction (PXRD)
X-ray powder diffraction patterns were collected in Bragg-Brentano geometry on an Analytical
Empyrean diffractometer equipped with a sealed tube (Cu Kα12, λ = 1.5418 Å) and a 1D X’Celerator
detector between 4 and 40 2θ degrees.
2.2.2. Differential Scanning Calorimetry (DSC)
Thermogravimetric experiments were carried out using sealed aluminium pans on a Netzsch
Polyma 214 differential scanning calorimeter. Temperature calibrations were made using indium as
the standard. An empty pan, sealed in the same way as the sample, was used as a reference. All the
thermograms were run at a heating/cooling rate of 20 ◦C·min−1 under a nitrogen purge at a rate of
50 mL·min−1.
2.2.3. Cambridge Structural Database (CSD) Analysis
The Cambridge Structural Database (CSD; version 5.40, November 2019) was searched for all
known mannitol solid forms. The calculated PXRD patterns for the various mannitol polymorphs
were obtained and further analysis was conducted with the PANalytical X’Pert HighScore software
package (version 4.7).
2.2.4. Equilibrium Solubility Measurements
Solubility measurements of mannitol were performed by adding 3 g mannitol to 10 mL of
degassed (via sonication), deionised H2O in 20 mL glass vials under constant stirring at 500 rpm.
Solubility measurements were conducted at 7, 10, 15, 20 and 25 ◦C using temperature-controlled
water baths. Once the solutions had been equilibrated for at least 24 h, a 2 mL sample was taken
from the liquid phase and filtered (PTFE filters, 0.45 µm pores) into a pre-weighed glass vial and
capped immediately. To avoid sampling errors, the syringes and filters were heated or cooled to the
corresponding temperature. The mass of the sample vials was measured after cooling for 1 h. The vials
were then uncapped and placed in a fume hood. Once evaporation was visibly complete, the vials
were placed in the oven overnight and once completely dry the vials were weighed again. The effects
of additives on mannitol solubility was determined as above in deionised H2O containing appropriate
concentrations of additives. This procedure was repeated in triplicate.
2.2.5. Continuous Cooling Experiments
All experiments were conducted in a 500 mL jacketed vessel (OPTIMAX 1001, Mettler Toledo,
Columbus, OH, USA) with an overhead stirrer (250 rpm) and a temperature control system (accurate to
0.1 ◦C). An in situ Focused Beam Reflectance Measurement (FBRM) (Particle Track G400, Mettler Toledo,
Columbus, OH, USA) probe was connected to a computer system to monitor the number of particles
and their size distribution during the runs.
The reactor was filled with 500 mL 20% w/v mannitol solution and heated to 45 ◦C for 5 min to
ensure complete dissolution of mannitol, the FBRM probe was calibrated in these conditions. Then the
reactor solution was brought to 25 ◦C and the solution was subsequently cooled to 0 ◦C at 0.1 K·min−1.
At the end of the experiment, the solution was brought back up to 45 ◦C for 5 min to dissolve the
mannitol. This procedure was repeated in triplicate.
2.2.6. Induction Time Experiments
Six vials containing 20% w/v mannitol solution were prepared and complete dissolution of
mannitol was obtained by heating (45 ◦C) and sonication for 5 min. All vials were then placed
immediately into a temperature-controlled water bath (at 10, 15 and 18 ◦C) and a nucleation event
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was determined by placing a backlight into the bath and recording the time at which the first crystal
was visible.
3. Results and Discussion
3.1. Characterisation of Crystals within Mannitol 20% w/v Infusion Solution
As received, the mannitol solution had large, visible crystal precipitates which were dissolved by
placing in an ultrasonic bath at 45 ◦C for 5 min (Branson®, Frequency 40 kHz). The infusion bag was
then placed onto a laboratory bench and, after one week, large crystals had again precipitated from
solution. The infusion bag was then cut open to isolate the crystals for further analysis (Figure 1).
To confirm the identity and purity of the precipitate, a number of the large needle-shaped
crystals were pulverised and analysed by PXRD and DSC (Figure 2). The PXRD pattern in Figure 2
suggests that the crystalline form of mannitol found in the infusion solution is the β polymorph,
DSC confirms its purity. These results are unsurprising as the α polymorph has been shown to
nucleate from supersaturated solutions and then transform to the stable β polymorph following
Oswald’s rule of stages [18]. Although the existence of a mannitol hydrate has been documented in the
literature, it is unstable [19]. This behaviour has been studied extensively for mannitol in aqueous
systems [13,15,16,18].
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3.2. Mannitol Solubility and Nucleation Characteristics in the 20% w/v Infusion Solution
Equilibrium solubility experiments were conducted between 7 and 25 ◦C (Figure 3) to understand
the stability of aqueous mannitol solutions across the range of temperatures they could be subjected to
during transport and storage.
Extrapolating from the data presented in Figure 3, mannitol 20% w/v infusion will become
supersaturated at ca. 21 ◦C and if stored at or below this temperature, crystallisation will be inevitable.
This is in agreement with published literature [14,20]. As clinical environments are known to fluctuate
between 15 and 25 ◦C there are moments when mannitol is stable and others where it is supersaturated
and therefore capable of crystallising at any time. As temperatures drop further away from 21 ◦C
supersaturation will increase, and so will nucleation rate [21]. Therefore, at the lower range of
temperatures found clinically or expected in transit, mannitol instability would be expected to become
increasingly difficult to manage. To the best of the authors’ knowledge, crystallisation kinetics of
mannitol is not known under conditions that mimic the clinical environment. Crystallisation kinetics
are dependent on the degree of supersaturation, influenced by the: temperature, concentration,
viscosity, medium and agitation amongst others [21,22]. Understanding crystal nucleation kinetics
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will enable an appreciation of the rate of instability and this was investigated by induction time and
continuous cooling crystallisation experiments [23].
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nuclea ion propensity of metastable fo ms which ca , in tur , induce the nucleatio of stable forms [22],
i.e., stirring could induc the nucleation of mannitol’s α polymorph which will transf rm to the stable
β polymorph [18]. Sti ring wou d falsely overestimate the instability issues of the mannitol infusion.
Figure 4 reveals that complete nucl ation occurs quickly at lower temperatures (e.g., <2 h at
10 ◦C) but can t ke several days at 18 ◦C. In c ntinuous cooling experiments (Figure 4) nucle
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exp ain the lack of att mpts to reformulate a stable alternativ . However, crystallis ion could eappear
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molarityi × ni × 1000 (1)
200 g
183 moles
× 1× 1000 = 1098 mOsmol·L−1 (2)
Table 1. Formulation approaches to achieve the target of 1098 mOsmol·L−1.
Formulation (w/v) Stable to (◦C) Mannitol mOsmol·L−1 Additive mOsmol·L−1
Mannitol (20%) 21 1098 -
Mannitol/Sorbitol (10%/10%) 10 549 549
Mannitol/Glycerol (10%/5%) 15 549 549
Mannitol/NaCl (7.54%/2%) 7 413.6 684.4
Each of the formulation additives studied could be utilised in a new, stable, hyperosmotic
formulation and the amount of each component can be tuned as desired so long as mannitol
concentration is below the equilibrium solubility (Table 1 and Figure 5). The choice of formulation
additive will be determined by the clinical application as each additive has its own advantages and
disadvantages. In vivo, sorbitol and glycerol are rapidly metabolised by the liver (therefore diminishing
its osmotic effect) and may increase the risk of complications for patients with diabetes [17]. Mannitol is
exclusively eliminated renally (indeed, this is a key feature of its therapeutic mechanism) and therefore
Pharmaceutics 2020, 12, 187 7 of 9
is not suitable for patients with renal insufficiency [17]. With NaCl, associated side effects include
myelinolysis and electrolyte imbalances [26]. In addition, the optimum administration protocol of
NaCl is not well understood although research is ongoing [27].
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4. Conclusions
This study fills an important gap in the literature describing the stability of 20% w/v mannitol
infusion solution across the range of conditions it will be exposed to before reaching the patient.
We have also evaluated a number of hyperosmolar alternatives which could be directly translated
to the clinic. The advantage of these formulations is three-fold as they are tuneable, stable and
therefore safer. Specifically, each formulation can be tuned by the pharmacist to suit the clinical
application, eliminati g the risk of recrystallisation i the controlled clinical environment (15–25 ◦C)
whilst maintaining the target osmolarity and perhaps enabling synergistic mechanisms of action.
Future work would include an evaluation of the safety and efficacy of this formulation in vivo;
particularly of interest would be a comparison of the efficacy of the mannitol/NaCl combination against
either component alone. Indeed, perhaps the ongoing debate surrounding the choice of hyperosmolar
therapy (salt vs. sugar [4]) reflects that both mannitol and NaCl have useful clinical effects in their
own right.
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